Product Description
Melphalan flufenamide (melflufen, Pepaxto®) is a peptide conjugated alkylating drug developed by Oncopeptides for the treatment of multiple myeloma (MM) and amyloid light-chain amyloidosis. It is an ethyl ester of a lipophilic dipeptide consisting of melphalan and para-fluoro-L-phenylalanine. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33961277/)
Mechanisms of Action: Alkylating Agent
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Belgium | Croatia | Czech | European Medicines Agency | Finland | Greece | Hungary | Iceland | Ireland | Italy | Lithuania | Poland | Portugal | Slovakia | Sweden | United States
Approved Indications: None
Known Adverse Events: None
Company: Oncopeptides AB
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Multiple Myeloma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| OCEAN | P3 |
Completed |
Multiple Myeloma |
2023-02-03 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/04/2024 |
News Article |
Oncopeptides expands on WODA partnership with addition of Africa and Eurasia to provide Pepaxti to Patients |
|
03/27/2024 |
News Article |
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa |
|
11/20/2023 |
News Article |
CARsgen Announces Formation of its Clinical Advisory Board |
|
09/01/2023 |
News Article |
Peptide-drug Conjugates (PDCs) Market Size, Share and Growth Factors Study |